Compare Charles River Laboratories Intl. Inc (CRL) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Kaltura Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Kaltura Inc trades at $1.3 (market cap $190.22M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 58.6× Kaltura Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| CRL | KLTR | |
|---|---|---|
Market Cap | $11.14B | $190.22M |
Sector | Health | Technology |
52-Week High | $233.60 | $1.97 |
52-Week Low | $145.57 | $1.08 |
Enterprise Value | $14.00B | $172.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
KLTR trades at $1.29, up 0.78% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $180M and narrowing losses, while maintaining a high gross margin of 71.17%. Recent news highlights industry recognition and AI product launches, though cash flow remains negative and equity is thin at $24.39M.
Outlook is mixed: analyst consensus leans buy (44%) with improving profit trends, but high P/B of 41.6 and negative ROE pose valuation risks. Key catalysts include Q2 2026 results on August 5, 2026, while competitive pressure and reliance on AI adoption present ongoing challenges for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
